Locteron: Additional Phase IIb data

Additional data from the international Phase IIb SELECT-2 trial in 116 treatment-naïve HCV patients showed that 320, 480 and 640 µg subcutaneous Locteron every other week led to lower increases in peak mean BDI scores from baseline vs. 1.5 µg/kg PegIntron peginterferon alfa-2b (67%, 30% and 31%, respectively, vs. 124%). Higher BDI scores indicate more severe depressive symptoms. Data were presented at the European Association for the Study of the Liver meeting in Berlin. ...